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Background: To examine the frequency of possible giant cell arteritis (GCA) symptoms (including headache,
temporal/scalp tenderness, jaw claudication and visual symptoms) in newly diagnosed polymyalgia rheumatica
(PMR) patients in UK primary care.
Methods: The PMR Cohort Study is a primary care inception cohort of 652 adults with newly diagnosed
polymyalgia rheumatica (PMR). At baseline, participants were asked to report (yes/no) on the presence of seven
potential GCA symptoms: sudden headache, tender scalp, disturbed/double vision, jaw claudication, fever, appetite
loss and unintentional weight loss.
Results: Of the 652 patients, 405 (62%) were female, with a mean (SD) age of 72.5 (8.9) years. Sudden headache was
the commonest symptom in 161 patients (24.7%). The least commonly reported symptom was jaw claudication in 66
(10.1%) patients. Females had a higher prevalence of headache, tender scalp and jaw pain. Sudden onset headache
and fever were commoner in younger patients, (OR (95% CI) per 10 year age band increase: headache 0.76 (0.62–0.92),
fever 0.63 (0.49, 0.79)). In those reporting sudden headache (n = 161), 19.9% (n = 32) also reported double/disturbed
vision and a tender scalp, whilst 11.8% (n = 19) reported double/disturbed vision and jaw pain.
Conclusion: The data suggests possible GCA symptoms are common in PMR patients, particularly sudden headache,
appetite loss and weight loss. These symptomatic PMR patients warrant careful monitoring and consideration for early
referral to specialist services.
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Giant cell arteritis (GCA, or temporal arteritis) is a systemic
large vessel vasculitis with a tendency to affect the aortic
and extracranial branches, such as superficial temporal
arteries [1]. GCA affects older adults (typically those
>50 years) with an estimated annual incidence of 1 per
10,000 per year in those over 40 years [2]. Its aetiology is
currently unknown, other than it is an immune mediated* Correspondence: s.hider@keele.ac.uk
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rheumatica (PMR) and females are affected up to three
times more frequently than males [3].
Prompt diagnosis and treatment of GCA is essential to
prevent complications such as irreversible blindness [4].
Common symptoms of GCA include headache, temporal/
scalp tenderness, jaw claudication and diplopia. However,
studies suggest that there may be an over-reliance on
headache as a presenting feature of GCA with one study
suggesting a prevalence of headache of 72%, [5], but with
audit data suggesting those without headache are at
increased risk of visual loss, perhaps as a consequence of
delayed recognition [6]. It is especially important for thosele is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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Table 1 Baseline Characteristics of the sample
N = 652
Age (Mean, SD) 72.5 (8.9)
Gender (N %)
Female 405 (62.1)
Male 247 (37.9)
Median (IQR) pain score (NRS) at presentation 8 (7, 9)
Median (IQR) stiffness score (NRS) at presentation 8 (7, 9)
Morning stiffness >45 min duration (n, %) 524 (80.3)
Current steroid dose for PMR treatment (mg/day)a
N (%)
<10 mg 64 (12.3)
10 < 15 mg 87 (16.7)
15 < 20 mg 218 (41.9)
20 < 25 mg 111 (21.4)
25-30 mg 6 (1.2)
≥30 mg 34 (6.5)
Smoking (n, %)
Never 317 (49.3%)
Previously 286 (44.5%)
Currently 40 (6.2%)
a Data on current steroid dose not available for 132 patients. NRS- numerical
rating scale, where 0 = none and 10 is very severe.
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GCA, as it has been reported in secondary care popula-
tions that between 16 and 21% [3, 7, 8] of those with PMR
will develop GCA at some point in their disease course.
However, this may be different in community populations
with PMR, and it is not clear to what extent this overlap is
present in the community setting. This study aims to
describe the prevalence of common symptoms that are
potentially indicative of GCA in a cohort of English adults
with incident PMR diagnosed in primary care.
Methods
Study design
The PMR Cohort Study is a cohort of 652 adults with
newly diagnosed PMR recruited in primary care. The
study has been described in detail elsewhere [9, 10].
Briefly, GP’s entering a first Read Code for PMR were
invited to refer patients into the study and encouraged to
request the recommended blood tests. All participating
general practices were provided with copies of the British
Society for Rheumatology guidelines for the management
of PMR [11]. Between June 2012 and June 2014, patients
with a new primary care diagnosis of PMR were referred
into the study by their GP and mailed a baseline question-
naire. This included information regarding PMR symp-
toms (current pain and stiffness using a numeric rating
scale (NRS)), lifestyle factors and socio-demographics.
Participants were also asked to report (yes/no) on the
presence of seven potential symptoms of GCA including
sudden onset headache, tender scalp, disturbed/double
vision, jaw pain on chewing, temperature/fever, appetite
loss and unintentional weight loss. Following completion
of the baseline questionnaire, participants were followed-
up by postal questionnaire at regular intervals for two
years, with medical record review at the end of the study
in those consenting, for recorded symptoms, treatment
and diagnoses. The current study uses data from the
baseline questionnaire only.
Statistical analysis
Descriptive statistics were used to describe the sample. The
prevalence of GCA symptoms was calculated as a percent-
age. Comparisons of prevalence were made across genders
and age (in 10-year age bands) using cross tabulation and
odds ratios with 95% confidence intervals. The prevalence
of pairs of GCA symptoms was also investigated using
simple descriptive statistics. As headache is an important
symptom of GCA, but is relatively common in the general
non-PMR population, the prevalence of combinations of
symptoms with headache were also investigated.
Results
Of the 652 incident PMR cases the mean (SD) age was
72.5 (8.9) years and 405 (62%) were female. Table 1shows the baseline demographics and clinical features of
the cohort. The median (IQR) time from referral into
the cohort to the baseline postal questionnaire being
received was 16 (11, 23) days. Sudden onset headache
(161, 24.7% patients), appetite loss (140, 21.5%) and
unintended weight loss (137, 21%) were the most com-
mon symptoms (Table 2). Females were significantly
more likely to report all symptoms than men, with the
exception of unintentional weight loss, where there was
no gender difference. (Table 2). Sudden onset headache
and fever were the only symptoms significantly associ-
ated with age, with younger patients more likely to
experience these symptoms (OR (95% CI) for headache
per 10-year increase 0.76; 0.62–0.92) and fever (OR (95%
CI) per 10-year increase 0.63 (0.49, 0.79)).
Pairs of GCA symptoms
In terms of symptom pairs, headache and tender scalp
were the most common combination pair of symptoms
with a prevalence of 10.1%, followed by headache and
double vision (9.5%) (Table 3). In those reporting sudden
headache (n = 161) (Table 2), 19.9% (n = 32) also
reported double/disturbed vision and a tender scalp,
whilst 11.8% (n = 19) reported double/disturbed vision
and jaw pain. Double/disturbed vision, tender scalp and
jaw pain was reported by 13 individuals (8.1%) reporting
sudden headache.
Table 2 Possible GCA Symptoms
All
(n = 652)
Female
(n = 405)
Male
(n = 247)
Odds Ratio (95% CI):
females vs. males (ref. category)
Mean (sd) age
with symptoms
Mean (sd) age
no symptoms
Odds Ratio (95% CI):
per 10 year age increase
Sudden headache 161
(24.7)
123
(30.4)
38
(15.4)
2.40
(1.60, 3.60)
70.8
(9.5)
73.1
(8.7)
0.76
(0.62, 0.92)
Appetite loss 140
(21.5)
102
(25.2)
38
(15.4)
1.85
(1.23, 2.80)
73.1
(9.2)
72.4
(8.9)
1.09
(0.88, 1.35)
Unintended weight loss 137
(21.0)
83
(20.5)
54
(21.9)
0.92
(0.63, 1.36)
73.3
(8.8)
72.3
(9.0)
1.14
(0.92, 1.42)
Tender scalp 123
(18.9)
87
(21.5)
36
(14.6)
1.60
(1.04, 2.45)
72.8
(8.9)
72.4
(9.0)
1.05
(0.84, 1.31)
Disturbed / double
vision
110
(16.9)
84
(20.7)
26
(10.5)
2.22
(1.39, 3.57)
71.6
(9.5)
72.7
(8.8)
0.87
(0.70, 1.09)
Temperature/ fever 99
(15.2)
72
(17.8)
27
(10.9)
1.76
(1.10, 2.83)
69.2
(9.4)
73.1
(8.7)
0.63
(0.49, 0.79)
Jaw pain on chewing 66
(10.1)
50
(12.4)
16
(6.5)
2.03
(1.13, 3.66)
72.3
(8.0)
72.5
(9.0)
0.98
(0.74, 1.30)
All are N (%) unless otherwise stated
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This study of incident PMR cases suggests that classical
GCA symptoms are common in newly diagnosed PMR
patients, with 1 in 4 patients reporting sudden headache,
appetite loss or unintentional weight loss. Jaw pain on
chewing was the least common reported symptom.
Except for unintentional weight loss, a higher proportion
of females reported all symptoms, whilst sudden head-
ache, double vision and fever were reported by fewer
people at older ages. Given that older patients seem to
be at greater risk of both developing GCA and of visual
loss (7) it may be that reporting of these symptoms is
more specific in older individuals, who may report fewer
symptoms but be at greater risk of complications. The
most common combination of symptoms was headache
with tender scalp and headache with double vision, each
affecting approximately 10% of the cohort at diagnosis.
Further follow up of the cohort will determine the
proportion of patients who were formally diagnosed as
having GCA.
The PMR Cohort study is the first inception cohort
study of PMR patients in primary care and is of a
substantial size. Although primary care recruitment can
be seen as a weakness, because no specialist opinion as
to the diagnosis was sought, this is also a major strength
of the study because the majority of patients with PMRTable 3 Symptom combinations in those with PMR
Symptom Combinations n (%)
Headache & Tender Scalp 66 (10.1%)
Headache & Double/Disturbed Vision 62 (9.5%)
Headache & Jaw Pain 39 (6.0%)
Headache & Tender Scalp & Jaw Pain 22 (3.4%)
Double/Disturbed Vision & Tender Scalp 41 (6.3%)
Double/Disturbed Vision & Jaw Pain 23 (3.5%)are diagnosed and managed exclusively in primary care
[12]. This sample is therefore free of the potential
spectrum bias that is likely to be present in studies
conducted in specialist settings where disease may be
more severe, atypical or difficult to manage. Reassuringly
however, the demographic and clinical characteristics of
this cohort are similar to other secondary care cohorts
[13], providing confidence in the accuracy of the primary
care PMR diagnosis. Furthermore symptoms were
recorded from patients close to the time of diagnosis
thus reducing the recall bias.
One of the limitations of this study is that at this stage
it is unknown if the patient was formally diagnosed with
GCA or not. The prevalence of possible GCA symptoms
was higher in women in our cohort, in common with
the reported higher prevalence of GCA in women. [7].
Furthermore, the study demonstrates that in patients
with PMR, headache is a much commoner symptom
than in the older adult general population. Work by
Steiner et al. [14] demonstrated that in the older adult
general population (aged 50–65) the prevalence of head-
ache was 3.4% for males and 13.5% for females The
prevalence of headache was considerably higher in our
cohort (males 15.4%, females 30.4%), suggesting that
PMR is associated with an increase in reported head-
aches, which may reflect the overlap with giant cell ar-
teritis, or that some cases of GCA are not being
recognised or misdiagnosed. Although females have a
higher prevalence of headaches overall, males saw a
much bigger increase in the prevalence of headaches
compared with a similar age general population group.
However, a Danish population survey suggested the
prevalence of headache to be 36.5%, although only 17%
had consulted primary care because of headache symp-
toms [15]. Previous studies comparing patients with
isolated PMR and those who went onto develop GCA
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dictor [16, 17], with others suggesting that the headache
is over-relied on in making a GCA diagnosis [5, 6].
Given that single symptoms such as headache are com-
mon both in the general population and in those with
PMR it may be that combinations of symptoms are more
useful in identifying patients at risk of GCA. Headache
and tender scalp are two of the most common symptoms
reported in those diagnosed with GCA and were reported
by around 10% of this PMR Cohort. Further follow-up will
assess whether these patients were initially misdiagnosed
as PMR instead of GCA, together with further assessment
of the utility of combinations of symptoms in predicting
those patients at higher risk of GCA.
Conclusions
In summary, within a cohort of primary care patients newly
diagnosed with PMR, symptoms suggestive of possible
GCA, such as headache, tender scalp and visual disturb-
ance are common. These occur in more than 1 in 4
patients and at higher rates than in the older age UK
general population. Given the risk of irreversible visual loss
in those with untreated GCA it may be that PMR patients
who have these symptoms warrant closer monitoring and
follow up to ensure that GCA does not develop and that
symptoms do not progress. Future follow-up of this cohort
will enable greater understanding of the proportions of
primary care PMR patients who develop GCA and the risk
factors for GCA development. Enabling risk stratification of
PMR patients could facilitate GP education (regarding
patients at higher risk) and more effective referral or treat-
ment interventions to reduce the impact of this potentially
serious complication.
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